Geriatric Population Creates Scope for the Asia-Pacific Interleukin Inhibitors Market Growth

The Asia-Pacific Interleukin Inhibitors market is anticipated to grow significantly at a CAGR of 10.9% over the forecast period (2021-2027). China, India, Japan, ASEAN, South Korea, and the Rest of Asia-Pacific are the key economies contributing to the growth of the market over the forecast period. The key aspect that drives the growth of the Asia-Pacific Interleukin Inhibitors market includes the rising geriatric population who are more prone to diseases such as arthritis and asthma. For instance, as per the United Nations (UN), in 2019, the percentage of the population aged 65 years and over in the country was 11.5%, which is expected to reach 16.9% by 2030. Hence, this is likely to create a wide scope for market growth in the region

Browse the full report description Asia-Pacific Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others) Forecast, 2021-2027 at https://www.omrglobal.com/industry-reports/asia-pacific-interleukin-inhibitors-market

Both, China and India hold 40% of the total world population share. As the population of India and China grows, its expanding share of older adults is particularly notable. The United Nations Population Division projects that India’s population age 50 years and older will reach 34% by 2050. Between 2010 and 2050, the share of people aged over 65 and older is expected to increase from 5% to 14%, while the share in the oldest age group (80 and older) will triple from 1% to 3%. Hence, with the age dynamics, these people are more prone to diseases such as arthritis, asthma, and others. This, in turn, creates scope for the market growth over the forecast period. 

Market Coverage

• Market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- By Product Type and Applications
• Region Covered- Asia-Pacific
• Competitive Landscape- Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in base year?
• Which segment will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Asia-Pacific Interleukin Inhibitors Market – Segmentation

By Product Type

• IL-1 Inhibitors
• IL-5 Inhibitors
• IL-6 Inhibitors
• IL-17 Inhibitors
• IL-23 Inhibitors

By Applications

• Arthritis
• Asthma
• Eczema
• Inflammatory Bowel Disease (IBD)
• Psoriasis
• Others

Asia-Pacific Interleukin Inhibitors Market – Countries Covered

Asia-Pacific           

• China
• India
• Japan
• ASEAN
• South Korea
• Rest of Asia-Pacific